Hologic faces M&A pressures; Myriad files another patent violation lawsuit;

> Pressured by activist investor Carl Icahn, diagnostic giant Hologic's ($HOLX) M&A prospects are heating up. Story

> Invitae said it will fight a patent violation lawsuit filed by Myriad Genetics ($MYGN) regarding Invitae's BRCA and MUTYH diagnostic tests. Item

> Duke University is evaluating the future of its Institute for Genome Sciences and Policy, following rumors that it will be disbanded next year. Story (reg. req.)

> Researchers have developed new computer models to help predict how patients dealing with a failing HIV therapy will respond to any new combination of drugs, no HIV genotype needed. Item

> A new study documented a 42% increase in parent-reported ADHD diagnoses from 2007 to 2011. Story

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.